Welcome to our dedicated page for Rxsight news (Ticker: RXST), a resource for investors and traders seeking the latest updates and insights on Rxsight stock.
RxSight, Inc. develops and sells ophthalmic medical technology for customized vision after cataract surgery. Its RxSight Light Adjustable Lens system includes Light Adjustable Lens products, the Light Delivery Device and related accessories, enabling post-operative adjustment of an intraocular lens based on patient visual feedback.
RxSight news commonly covers financial results, sales guidance, Light Adjustable Lens unit demand, Light Delivery Device placements and installed-base growth. Company updates also address clinical evidence presented in cataract and refractive surgery forums, regulatory approvals in international markets, healthcare conference participation and executive finance leadership changes.
RxSight, Inc. announced a proposed public offering of $100 million of its common stock, with an additional 15% option for underwriters. The company plans to use the proceeds for commercial expansion, product development, research, and working capital. BofA Securities, J.P. Morgan, and BTIG are involved in the offering. An automatic shelf registration statement was filed with the SEC. The offering will be made through a prospectus supplement and accompanying prospectus.
RxSight, Inc. reported strong first quarter 2024 financial results, with a revenue of $29.5 million, a 69% increase compared to the first quarter of 2023. The company sold 20,218 Light Adjustable Lenses (LAL) and 66 Light Delivery Devices (LDD), showing significant growth in procedure volume and unit sales. Gross profit increased to $20.7 million, operating expenses rose to $31.4 million, and the company reported a net loss of $(9.1) million. However, adjusted net loss improved to $(4.4) million. Cash, cash equivalents, and short-term investments were $125.4 million as of March 31, 2024. RxSight raised its 2024 revenue guidance to $132.0 million to $137.0 million, gross margin guidance to 68% to 70%, and operating expense guidance to $126.0 million to $130.0 million.
RxSight, Inc., a medical device company specializing in customized vision after cataract surgery, will be presenting at the Bank of America Healthcare Conference on May 15, 2024. The presentation will be available for viewing online.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.